Nick Lonardo

Nick Lonardo

Auto-generated profile, based on publicly available information

Nick Lonardo

Department of Pharmacy Services, University of Utah Health, Salt Lake City, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
NLNick W. Lonardo
Nick W. Lonardo
MMMary C. Mone
Mary C. Mone
RNRaminder Nirula
Raminder Nirula
EKEdward J. Kimball
Edward J. Kimball
KLKyle Ludwig
Kyle Ludwig
RBRichard G. Barton
Richard G. Barton
Rationale: Mechanically ventilated intensive care unit (ICU) patients are frequently managed using a continuous-infusion sedative. Although recent guidelines suggest avoiding benzodiazepines for sedation, this class of drugs is still widely used. There are limited data comparing sedative agents in terms of clinical outcomes in an ICU setting. Objectives: Comparison of propofol to midazolam and lorazepam in adult ICU patients. Methods: Data were obtained from a multicenter ICU database (2003–2009). Patient selection criteria included age greater than or equal to 18 years, single ICU admission with single ventilation event (>48 h), and treatment with continuously infused sedation (propofol, midazolam, or lorazepam). Propensity score analysis (1:1) was used and mortality measured. Cumulative incidence and competing risk methodology were used to examine time to ICU discharge and ventilator removal. Measurements and Main Results: There were 2,250 propofol-midazolam and 1,054 propofol-lorazepam matched patients. Hospital mortality was statistically lower in propofol-treated patients as compared with midazolam- or lorazepam-treated patients (risk ratio, 0.76; 95% confidence interval [CI], 0.69–0.82 and risk ratio, 0.78; 95% CI, 0.68–0.89, respectively). Competing risk analysis for 28-day ICU time period showed that propofol-treated patients had a statistically higher probability for ICU discharge (78.9% vs. 69.5%; 79.2% vs. 71.9%; P < 0.001) and earlier removal from the ventilator (84.4% vs. 75.1%; 84.3% vs. 78.8%; P < 0.001) when compared with midazolam- and lorazepam-treated patients, respectively. Conclusions: In this large, propensity-matched ICU population, patients treated with propofol had a reduced risk of mortality and had both an increased likelihood of earlier ICU discharge and earlier discontinuation of mechanical ventilation.

3 February 2015 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
HSHannah L. Spinner
Hannah L. Spinner
NLNick W. Lonardo
Nick W. Lonardo
RMRoja Mulamalla
Roja Mulamalla
JSJosef Stehlik
Josef Stehlik

1 August 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
VWVanessa Wall
Vanessa Wall
KFKory I. Fleming
Kory I. Fleming
JTJoseph Tonna
Joseph Tonna
JNJade Nunez
Jade Nunez
NLNick Lonardo
Nick Lonardo
CPChristopher J. Pannucci
Christopher J. Pannucci

28 August 2018 in Pharmacy
Verified
Journal Article
Open access
PDF file
JLJessica Louie
Jessica Louie
NLNick W. Lonardo
Nick W. Lonardo
MMMary C. Mone
Mary C. Mone
VSVanessa W. Stevens
Vanessa W. Stevens
RDRishi Deka
Rishi Deka
RBRichard G. Barton
Richard G. Barton
Objective: Compare the duration of mechanical ventilation between patients receiving sedation with continuous infusions of propofol alone or combination with the use of dexmedetomidine and propofol. Design: Retrospective, propensity matched (1:1) cohort study, employing eight variables chosen a priori for matching. Timing of exposure to dexmedetomidine initiation was incorporated into a matching algorithm. Setting: Level 1, university-based, 32-bed, adult, mixed trauma and surgical intensive care unit (SICU). Continuous sedation was delivered according to a protocol methodology with daily sedation vacation and spontaneous breathing trials. Choice of sedation agent was physician directed. Patients: Between 2010 and 2014, 149 SICU patients receiving mechanical ventilation for >24 h received dexmedetomidine with propofol. Propensity matching resulted in 143 pair cohorts. Interventions: Dexmedetomidine with propofol or propofol alone. Measurements and Main Results: There was no statistical difference in SICU length of stay (LOS), with a median absolute difference of 5.3 h for propofol alone group (p = 0.43). The SICU mortality was not statistically different (RR = 1.002, p = 0.88). Examining a 14-day period post-treatment with dexmedetomidine, on any given day (excluding days 1 and 14), dexmedetomidine with propofol-treated patients had a 0.5% to 22.5% greater likelihood of being delirious (CAM-ICU positive). In addition, dexmedetomidine with propofol-treated patients had a 4.5% to 18.8% higher likelihood of being above the target sedation score (more agitated) compared to propofol-alone patients. Conclusions: In this propensity matched cohort study, adjunct use of dexmedetomidine to propofol did not show a statistically significant reduction with respect to mechanical ventilation (MV) duration, SICU LOS, or SICU mortality, despite a trend toward receiving fewer hours of propofol. There was no evidence that dexmedetomidine with propofol improved sedation scores or reduced delirium.

1 October 2003
Verified
Journal Article
Closed access
RKRichard Koehler
Richard Koehler
MMMary Mone
Mary Mone
EKEdward Kimball
Edward Kimball
DVDaniel Vargo
Daniel Vargo
NLNick Lonardo
Nick Lonardo
RBRichard Barton
Richard Barton

1 July 2016 in Hospital Pharmacy
Verified
Journal Article
Closed access
TSTyler Sledge
Tyler Sledge
NLNick Lonardo
Nick Lonardo
HSHeidi Simons
Heidi Simons
WSWayne Shipley
Wayne Shipley
Background: Critical care pharmacists are established and valuable members of the critical care team, however there is rarely written evidence of their daily involvement in the patient's electronic medical record (EMR). Documentation in the EMR has the advantage of ensuring a seamless pass-off and provides an opportunity to capture the pharmacist's cognitive and clinical impact in a way that traditional systems of tracking “interventions” fail to do. We investigated implementation of pharmacist progress notes in a surgical intensive care unit (ICU) and their utility in measuring pharmacist activity. Methods: Daily pharmacist progress notes written in a surgical ICU over a period of 2 months were reviewed. Each pharmacist action identified through progress note review was quantified and scored by an independent reviewer using a newly developed scoring system, the clinical impact score (CIS). This was developed as a way to quantify pharmacist actions and to classify those actions by clinical impact. Results: Four hundred sixty-two daily pharmacist progress notes were reviewed over a 2-month period. There were 1,055 actions identified that resulted in a therapy change. Four of these actions resulted in the potential avoidance of a sentinel event. Of patients with at least 5 progress notes ( n = 44), the majority of pharmacist actions occurred on ICU day 1. Conclusion: The results of this descriptive study demonstrate that the implementation of daily pharmacist progress notes is feasible in an advanced practice setting, and the pharmacist's contribution to patient care may be obtained through review of this documentation in the patient's medical record. The critical care pharmacist's daily involvement in patient care most commonly results in optimization of pharmacotherapy and avoidance of drug misadventure.